NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $104 | -30.7% | 2,500 | 0.0% | 0.01% | -28.6% |
| Q1 2023 | $150 | -18.0% | 2,500 | 0.0% | 0.01% | -30.0% |
| Q4 2022 | $183 | -99.9% | 2,500 | 0.0% | 0.01% | -9.1% |
| Q3 2022 | $190,000 | +9.2% | 2,500 | 0.0% | 0.01% | +22.2% |
| Q2 2022 | $174,000 | -15.9% | 2,500 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $207,000 | +10.1% | 2,500 | 0.0% | 0.01% | +28.6% |
| Q4 2021 | $188,000 | -35.2% | 2,500 | 0.0% | 0.01% | -41.7% |
| Q3 2021 | $290,000 | -79.2% | 2,500 | -60.3% | 0.01% | -80.6% |
| Q2 2021 | $1,397,000 | +64.9% | 6,300 | -1.6% | 0.06% | +44.2% |
| Q1 2021 | $847,000 | +179.5% | 6,400 | +265.3% | 0.04% | +152.9% |
| Q4 2020 | $303,000 | +56.2% | 1,752 | +0.5% | 0.02% | +41.7% |
| Q3 2020 | $194,000 | +79.6% | 1,743 | -4.0% | 0.01% | +50.0% |
| Q2 2020 | $108,000 | -36.5% | 1,815 | -28.0% | 0.01% | -42.9% |
| Q1 2020 | $170,000 | -25.1% | 2,521 | -6.5% | 0.01% | -12.5% |
| Q4 2019 | $227,000 | – | 2,696 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |